To give or not to give? A critical appraisal of a clinical trial on radioiodine treatment
Publication date
2022-08
Authors
Tuncel, Murat
Vrachimis, Alexis
Campenni, Alfredo
de Keizer, Bart
Verburg, Frederik A.
Kreissl, Michael C.
Ovcaricek, Petra Petranovic
Geliashvili, Tamara
Giovanella, Luca
Editors
Advisors
Supervisors
Document Type
Editorial
Metadata
Show full item recordCollections
License
taverne
Abstract
Recently , Leboulleux et al. published the results of the ESTIMABL 2 trial [1]. It is an open-label, randomised, phase III trial using a noninferiority comparison design. In this study, included patients were at the lowest-risk end of the low-risk spectrum of differentiated thyroid cancer (DTC) treated with total thyroidectomy with or without lymph node dissection. Patients were randomised to receive low-dose postoperative radioiodine therapy (RAI) with 1.1 GBq in one group and follow-up without RAI in the second group. We congratulate the authors for this work, representing one of the few randomised trials available in the field. However, we would point out some potential limitations that need to be considered before translating these results to generalised clinical recommendations.
Keywords
Clinical Trial Protocols as Topic, Humans, Iodine Radioisotopes/therapeutic use, Thyroid Neoplasms/drug therapy, Taverne, Radiology Nuclear Medicine and imaging, Editorial
Citation
Tuncel, M, Vrachimis, A, Campenni, A, de Keizer, B, Verburg, F A, Kreissl, M C, Ovcaricek, P P, Geliashvili, T & Giovanella, L 2022, 'To give or not to give? A critical appraisal of a clinical trial on radioiodine treatment', European Journal of Nuclear Medicine and Molecular Imaging, vol. 49, no. 10, pp. 3316-3319. https://doi.org/10.1007/s00259-022-05841-6